Skip to main content

Vacuum Erection Device (VED)

The vacuum erection device (VED) is a non-invasive mechanical device that uses negative pressure to draw blood into the corpora cavernosa, producing an erection that can be maintained with a constriction ring. FDA-approved since 1982, it remains a versatile tool across erectile dysfunction (ED) of any etiology, post-radical-prostatectomy penile rehabilitation, Peyronie's disease adjunctive therapy, and pre / post penile prosthesis optimization.[1][2][3]

Mechanism — two functional modes​

VEDs operate in two distinct modes[2]:

Vacuum Constriction Device (VCD) — for intercourse​

  • Negative pressure applied via a cylinder distends corporal sinusoids, drawing blood into the corpora cavernosa.
  • An external constriction ring at the base of the penis prevents venous outflow, maintaining the erection.
  • This produces a passive erection — blood is trapped regardless of arterial inflow or nerve function. Ring must not exceed 30 minutes to avoid penile ischemia.[4]

VED for rehabilitation — without constriction ring​

  • The same negative-pressure mechanism is used without a ring, purely to increase corporal blood oxygenation and tissue perfusion.[2][5]
  • Rationale: artificial induction of erections facilitates tissue oxygenation, reduces cavernosal fibrosis, and preserves smooth-muscle integrity in the absence of nocturnal erections.

The underlying biology involves increased peak flow and elasticity of cavernous arteries, preservation of corporal smooth muscle, and prevention of veno-occlusive dysfunction through regular tissue engorgement.[6]

Clinical indications and evidence​

Erectile dysfunction — primary indication​

The AUA 2018 ED Guideline recognizes VED as a treatment option for ED, available OTC or by prescription.[7]

PopulationVED efficacy rateSource
Mixed etiologies82.9%Zhang 2025 SR/meta (18 studies, n=1,065)[8]
Post-radical prostatectomy84.5%Zhang 2025
Diabetes mellitus73.0%Zhang 2025
Spinal cord injury71.8%Zhang 2025
Pooled refractory ED (PDE5i non-responders)80% (95% CI 0.76–0.84)Zhang 2025
Long-term continuation83.5% (n=5,847 survey)Lewis 1997[9]

Positioning. Generally considered a second-line therapy after PDE5i failure, though in select populations (post-RP, PDE5i-contraindicated patients) may be first-line. The ADA 2026 Standards of Care lists VEDs among treatments for diabetic ED not responding to PDE5is.[10][11]

Combination with PDE5 inhibitors. Sun 2014: in diabetic men with moderate-to-severe ED who failed sildenafil monotherapy, sildenafil 100 mg + VED improved IIEF significantly more than VED alone (17.53 vs 14.29 at 3 mo, p < 0.05).[12]

Post-radical-prostatectomy penile rehabilitation​

VED is a cornerstone of penile rehabilitation after radical prostatectomy because it draws blood into the penis regardless of nerve integrity.[2][5]

  • Pirola 2024 Int J Impot Res scoping review of 16 studies — VED after RP consistently improved IIEF-5, conserved penile length, and supported satisfactory intercourse vs controls. Results were better in patients enrolled in dedicated VED programs that enhanced compliance.[6]
  • Feng 2022 SR/meta — IIEF-5 significantly higher with VED at 6–9 mo post-RP (MD 6.70, 95% CI 2.30–11.10, p = 0.003).[13]
  • Nauta 2025 academic penile-rehab program (n = 570; PDE5i + VED ± ICI): 2-yr EF-recovery rates 75–80% in patients with good baseline function.[14]
  • Basal 2013 — PDE5i + VED produced the shortest EF-recovery period after bilateral nerve-sparing RP.[15]
  • VED's effectiveness in accelerating spontaneous (unassisted) erectile-function recovery remains uncertain.[5]

Typical post-RP protocol: daily VED use without a ring, beginning as early as 1 month post-surgery, often combined with PDE5i.[6][16]

Peyronie's disease — adjunct, not monotherapy​

VED has a more limited but emerging role in PD, distinct from penile traction therapy[3][17]:

  • Animal model (Lin 2017) — VED reduced penile curvature vs untreated controls (28.4° vs 38.6°, p < 0.05).[17]
  • Combined with CCH injections — Ralph 2017 RCT (n=30) of CCH + VED ± modeling: mean curvature improvement −23.3° to −23.7° at 36 wk; 85–93% global responders. Alzubaidi 2025 retrospective (n=99) of CCH + VED + daily tadalafil: mean 21.4% curvature improvement.[18][19]
  • Post-IPP scratch technique (Antonini 2018) — VED twice daily after IPP placement reduced residual curvature from 14–22° to 8–9° over 24 wk.[20]
  • Current evidence favors traction devices over VED for curvature correction; VED may be preferred for its erectile-function benefits.[3]

Pre- and post-penile-prosthesis optimization​

VED plays distinct roles in perioperative IPP management.[21][22]

Preoperative — corporal-fibrosis preparation.

  • Tsambarlis 2017 in men with severe corporal fibrosis (prior prosthesis infection or ischemic priapism): VED 10–15 min twice daily for ≥ 3 months softened fibrosis and enabled successful three-piece IPP placement in all 13 patients, with mean stretched-length increase of +0.92 cm.[23]
  • Recommended for at least 1 month preoperatively to optimize corporal tissue.[21]

Postoperative — length and girth preservation.

  • Antonini 2020 (n=74, AMS LGX 700 IPP, VED 5 min twice daily for 1 yr): penile length 14 → 17 cm median; girth 9 → 11 cm median; IIEF-5 9 → 25 (p < 0.001).[24]
  • VED has been shown to increase both penile length and circumference after prosthesis surgery — a notable advantage over traction therapy, which does not affect girth.[22]
  • Postoperative VED without a ring for 12 weeks alongside pump-inflation protocols.[21]

Cosmetic / aesthetic penile lengthening — minimal evidence​

Unlike penile traction therapy, VED has shown minimal efficacy for cosmetic elongation.[25]

  • Aghamir 2006 (n=37, VED 3×/wk × 6 mo): non-significant SPL increase 7.6 → 7.9 cm (~ 10%); only 30% satisfaction.[25]
  • Oderda-Gontero 2011 SR concluded penile extenders (traction devices) — not VED — are the only evidence-based non-surgical lengthening intervention.[26]

Devices​

FeatureMedical-grade VEDOver-the-counter VED
FDA regulationYes — pressure-limiting mechanismVariable; may lack safety features
Constriction ringIncludedMay or may not include
Pressure limitBuilt-in gauge to prevent excessive vacuumOften absent
Insurance coverageMay be covered (Rx required)Not covered
CostHigher initialLower
Best-studied deviceOsbon ErecAid (Timm Medical)[3]Various

The Osbon ErecAid is the most well-studied vacuum device across indications.[3] Salvatore 1991 — regular users scored Osbon ErecAid, Mentor Response, and Mentor-Piston highest for ease of use; 100% of novice users preferred single-handed devices.[27]

Safety​

VED is consistently safe with transient, minor adverse events.[8][28][9][7]

Common adverse events​

  • Penile bruising / petechiae — pooled incidence 24.3% (higher in SCI 31.4%).[8]
  • Penile numbness; discomfort or pain.
  • Delayed or blocked ejaculation (constriction ring impedes antegrade ejaculation).
  • Cold penile sensation.
  • Pivoting at the penile base — erection is rigid distal to the ring but not proximal.

Contraindications and cautions[29][9][7]​

  • Anticoagulant therapy or bleeding disorders — increased risk of penile hemorrhage.
  • History of unexplained intermittent priapism.
  • Sickle-cell disease or other priapism-predisposing conditions.
  • Constriction ring must not exceed 30 minutes — penile ischemia risk.[28]
  • ASIA 2022 — VED not recommended with anticoagulants or with a history of Peyronie's disease (for the VCD-with-ring mode).[29]

Pressure-limiting mechanism. Medical-grade devices include a built-in pressure-limiting feature to prevent excessive vacuum that could cause tissue damage. Non-medical-grade devices may lack this feature.[29]

Practical considerations​

  • Patient selection: best for men in stable relationships who have failed or cannot use PDE5is and who prefer a non-pharmacological option.[28]
  • Partner involvement is often important, particularly for patients with limited hand dexterity.[4]
  • Initial medical supervision is recommended while learning to use the device. Instructional videos rated essential by 80–95% of users.[27]
  • Lubrication should always be used to prevent skin damage.[29]
  • Satisfaction is more variable than efficacy. Clinical efficacy 70–90%; ~ 50% of patients report dissatisfaction with the mechanical / unnatural quality of the erection. Long-term continuation rates are high (83.5%).[28][9]

Guideline positioning​

BodyPosition
AUA 2018 ED Guideline[7]Recognizes VED as a treatment option for ED; cautions about anticoagulants, bleeding disorders, priapism history
ADA 2026 Standards of Care[10][11]Lists VED among treatments for diabetic ED not responding to PDE5is
ACS Prostate Cancer Survivorship[30]Recommends VED for post-RP ED; combination therapy (e.g., sildenafil + VED) managed with urology
ICSM 2016 Penile Prosthesis[31]Recognizes VED in the treatment algorithm before prosthesis and as a rehabilitation tool
ASIA 2022 SCI Durable Medical Equipment[29]Recommends VED for SCI patients; notes dexterity requirements and anticoagulant contraindication

See Also​

Penile Traction Therapy · Peyronie's Disease (Male Sexual Dysfunction atlas) · Penile Implants · Erectile Dysfunction (clinical conditions) · PDE5 Inhibitors · Intracavernosal Injection Agents

References​

1. Brison D, Seftel A, Sadeghi-Nejad H. The resurgence of the vacuum erection device (VED) for treatment of erectile dysfunction. J Sex Med. 2013;10(4):1124-1135. doi:10.1111/jsm.12046

2. Yuan J, Hoang AN, Romero CA, et al. Vacuum therapy in erectile dysfunction — science and clinical evidence. Int J Impot Res. 2010;22(4):211-219. doi:10.1038/ijir.2010.4

3. Sultana A, Grice P, Vukina J, Pearce I, Modgil V. Indications and characteristics of penile traction and vacuum erection devices. Nat Rev Urol. 2022;19(2):84-100. doi:10.1038/s41585-021-00532-7

4. Hentzen C, Musco S, Amarenco G, Del Popolo G, Panicker JN. Approach and management to patients with neurological disorders reporting sexual dysfunction. Lancet Neurol. 2022;21(6):551-562. doi:10.1016/S1474-4422(22)00036-9

5. Shu T, Ren D, Wang R. The role of vacuum erection device and penile traction therapy in the patients after radical prostatectomy: a narrative review. Int J Impot Res. 2025. doi:10.1038/s41443-025-01092-9

6. Pirola GM, Naselli A, Maggi M, et al. Vacuum erection device for erectile function rehabilitation after radical prostatectomy: which is the correct schedule? Results from a systematic, scoping review. Int J Impot Res. 2024;36(3):194-200. doi:10.1038/s41443-023-00700-w

7. Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633-641. doi:10.1016/j.juro.2018.05.004

8. Zhang F, Luo Z, Xue Q, et al. Efficacy of vacuum erectile device in refractory erectile dysfunction: a systematic review and meta-analysis. Int J Impot Res. 2025. doi:10.1038/s41443-025-01102-w

9. Lewis RW, Witherington R. External vacuum therapy for erectile dysfunction: use and results. World J Urol. 1997;15(1):78-82. doi:10.1007/BF01275162

10. American Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes — 2026. Diabetes Care. 2026;49(Suppl 1):S61-S88. doi:10.2337/dc26-S004

11. American Diabetes Association Professional Practice Committee. 12. Retinopathy, neuropathy, and foot care: standards of care in diabetes — 2026. Diabetes Care. 2026;49(Suppl 1):S261-S276. doi:10.2337/dc26-S012

12. Sun L, Peng FL, Yu ZL, Liu CL, Chen J. Combined sildenafil with vacuum erection device therapy in the management of diabetic men with erectile dysfunction after failure of first-line sildenafil monotherapy. Int J Urol. 2014;21(12):1263-1267. doi:10.1111/iju.12564

13. Feng D, Tang C, Liu S, et al. Current management strategy of treating patients with erectile dysfunction after radical prostatectomy: a systematic review and meta-analysis. Int J Impot Res. 2022;34(1):18-36. doi:10.1038/s41443-020-00364-w

14. Nauta MD, Falagario UG, Ricapito A, et al. Sexual function recovery following open and robotic radical prostatectomy: results of an academic penile rehabilitation program. Asian J Androl. 2025. doi:10.4103/aja202525

15. Basal S, Wambi C, Acikel C, Gupta M, Badani K. Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function. BJU Int. 2013;111(4):658-665. doi:10.1111/j.1464-410X.2012.11487.x

16. Bock M, Burns RT, Pereira TA, Bernie HL. A contemporary review of the treatments and challenges associated with penile rehabilitation after radical prostatectomy including a proposed optimal approach. Int J Impot Res. 2024;36(5):480-485. doi:10.1038/s41443-023-00782-6

17. Lin H, Liu C, Wang R. Effect of penile traction and vacuum erectile device for Peyronie's disease in an animal model. J Sex Med. 2017;14(10):1270-1276. doi:10.1016/j.jsxm.2017.08.011

18. Ralph DJ, Abdel Raheem A, Liu G. Treatment of Peyronie's disease with collagenase clostridium histolyticum and vacuum therapy: a randomized, open-label pilot study. J Sex Med. 2017;14(11):1430-1437. doi:10.1016/j.jsxm.2017.08.015

19. Alzubaidi RT, Abdelkareem M, Al-Zoubi RM, et al. Outcomes and management of Peyronie's disease with combined treatment of collagenase clostridium histolyticum, vacuum erection device, and tadalafil. Asian J Androl. 2025. doi:10.4103/aja202514

20. Antonini G, De Berardinis E, Del Giudice F, et al. Inflatable penile prosthesis placement, scratch technique and postoperative vacuum therapy as a combined approach to definitive treatment of Peyronie's disease. J Urol. 2018;200(3):642-647. doi:10.1016/j.juro.2018.04.060

21. Krishnappa P, Matippa P, Fraile-Poblador A, Lledo-Garcia E, Moncada I. Penile length preservation in penile prosthesis placement: tips & tricks. Int J Impot Res. 2025. doi:10.1038/s41443-025-01123-5

22. Łaszkiewicz J, Berardinis E, Krajewski W, et al. Perioperative therapies and techniques to enhance penile dimensional and functional outcomes following inflatable penile prosthesis implantation: a contemporary 10-year systematic review. Asian J Androl. 2026;28(1):31-37. doi:10.4103/aja2024105

23. Tsambarlis PN, Chaus F, Levine LA. Successful placement of penile prostheses in men with severe corporal fibrosis following vacuum therapy protocol. J Sex Med. 2017;14(1):44-46. doi:10.1016/j.jsxm.2016.11.304

24. Antonini G, De Berardinis E, Busetto GM, et al. Postoperative vacuum therapy following AMS™ LGX 700® inflatable penile prosthesis placement: penile dimension outcomes and overall satisfaction. Int J Impot Res. 2020;32(1):133-139. doi:10.1038/s41443-019-0125-z

25. Aghamir MK, Hosseini R, Alizadeh F. A vacuum device for penile elongation: fact or fiction? BJU Int. 2006;97(4):777-778. doi:10.1111/j.1464-410X.2006.05992.x

26. Oderda M, Gontero P. Non-invasive methods of penile lengthening: fact or fiction? BJU Int. 2011;107(8):1278-1282. doi:10.1111/j.1464-410X.2010.09647.x

27. Salvatore FT, Sharman GM, Hellstrom WJ. Vacuum constriction devices and the clinical urologist: an informed selection. Urology. 1991;38(4):323-327. doi:10.1016/0090-4295(91)80144-v

28. Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013;381(9861):153-165. doi:10.1016/S0140-6736(12)60520-0

29. American Spinal Injury Association. Durable medical equipment guidelines for persons with spinal cord injury or dysfunction (Update 2022). 2022.

30. Skolarus TA, Wolf AM, Erb NL, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin. 2014;64(4):225-249. doi:10.3322/caac.21234

31. Levine LA, Becher EF, Bella AJ, et al. Penile prosthesis surgery: current recommendations from the International Consultation on Sexual Medicine. J Sex Med. 2016;13(4):489-518. doi:10.1016/j.jsxm.2016.01.017